Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2B | Q14289 | 3/20 | 0.54 |
| ▸ | MET | P08581 | 13/20 | 0.52 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.51 |
| ▸ | EIF2AK3 | Q9NZJ5 | 2/20 | 0.50 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.50 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20022509 | 0.95 | PTK2B (0.57) | PTK2BMETPTK2EIF2AK3EIF2AK4 | |
| SCHEMBL20022533 | 0.93 | MET (0.52) | PTK2BMETPTK2EIF2AK3EIF2AK4 | |
| SCHEMBL20022498 | 0.89 | MET (0.55) | PTK2BMETPTK2EIF2AK3EIF2AK4 | |
| SCHEMBL20022421 | 0.87 | MET (0.58) | PTK2BMETPTK2IGF1RKDR | |
| SCHEMBL20022552 | 0.86 | PTK2B (0.57) | PTK2BMETPTK2EIF2AK3EIF2AK4 | |
| SCHEMBL20022484 | 0.86 | PTK2B (0.57) | PTK2BMETPTK2EIF2AK3EIF2AK4 | |
| SCHEMBL18163412 | 0.85 | MET (0.52) | PTK2BMETPTK2IGF1RKDR | |
| SCHEMBL20022422 | 0.85 | MET (0.62) | PTK2BMETPTK2IGF1RKDR | |
| SCHEMBL18163411 | 0.85 | MET (0.58) | PTK2BMETPTK2EIF2AK3EIF2AK4 | |
| SCHEMBL18163636 | 0.85 | MET (0.58) | PTK2BMETPTK2IGF1RKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934274-B2 | Quinoline derivatives as TAM RTK inhibitors | QURIENT CO., LTD. (KR) | 2021-03-02 | — | — | US | disclosed |
| US-20180093968-A1 | QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2018-04-05 | — | — | US | disclosed |
| US-20180093968-A1 | QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934274-B2 | Quinoline derivatives as TAM RTK inhibitors | TYRO3, MERTK, AXL | PTK2B 28/4885MET 5/4885PTK2 80/4885 |
| US-20180093968-A1 | QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS | TYRO3, MERTK, AXL | PTK2B 28/4885MET 5/4885PTK2 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.